Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JAVADIN vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JAVADIN is a synthetic flavonoid derivative that acts as a potent inhibitor of viral RNA-dependent RNA polymerase (Rd Rp), thereby blocking viral replication. It also modulates the host immune response by upregulating interferon signaling and reducing pro-inflammatory cytokine production.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Treatment of chronic hepatitis C virus (HCV) infection in combination with other antiviral agents,Investigational use for emerging viral infections such as COVID-19
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
400 mg orally once daily
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life is 8.2 hours (range 6.5–10.1) in patients with normal renal function; prolonged to 18–24 hours in moderate renal impairment (Cr Cl 30–50 m L/min).
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Primarily metabolized by CYP3A4 and CYP2C9 isoenzymes in the liver. Minor contribution from glucuronidation via UGT1A1. Active metabolite M1 is formed and further cleared renally.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Renal elimination of unchanged drug accounts for 85% of clearance; biliary/fecal elimination accounts for 10%; 5% metabolized.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
92% bound to albumin and alpha-1-acid glycoprotein.
47% bound to plasma proteins (primarily albumin)
1.2 L/kg (range 0.9–1.5), indicating extensive tissue distribution with high affinity for liver and kidney.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Oral: 75% (range 60–85%) due to first-pass metabolism; intramuscular: 95%.
IV: 100% (only IV route); oral: not approved
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: 200 mg once daily; e GFR <15 m L/min: not recommended
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Weight ≥40 kg: 400 mg once daily; Weight 20-39 kg: 200 mg once daily; Weight <20 kg: not established
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment; monitor renal function due to age-related decline
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
WARNING: HEPATOTOXICITY. JAVADIN can cause severe hepatic injury, including acute liver failure. Monitor liver function tests (LFTs) before and during treatment. Discontinue if signs of hepatic decompensation occur.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Hepatotoxicity (see black box warning); QT interval prolongation (avoid use in patients with baseline QTc >450 ms); myelosuppression (monitor CBC); drug interactions with strong CYP3A4 inducers/inhibitors; photosensitivity reactions; pancreatitis (discontinue if symptoms develop).
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Absolute: History of hypersensitivity to JAVADIN or any component; severe hepatic impairment (Child-Pugh class C); concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Relative: Moderate hepatic impairment (Child-Pugh class B), pregnancy (limited data), breastfeeding, history of prolonged QT syndrome.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Take with meals to minimize GI side effects. Avoid grapefruit juice as it may alter drug metabolism. No other significant food restrictions.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
FDA Pregnancy Category C. First trimester: potential for neural tube defects and cardiac malformations based on animal studies; limited human data. Second and third trimesters: risk of fetal hypotension, renal impairment, and oligohydramnios due to decreased placental perfusion. Avoid use unless benefit outweighs risk.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in nursing infants including hypotension and renal impairment. Breastfeeding is not recommended during therapy and for at least 24 hours after last dose.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
Increased plasma volume and renal clearance in pregnancy may require dose escalation; however, higher doses increase fetal risk. No established dose adjustments available. Use lowest effective dose with careful monitoring. Empirical dose increase by 25-50% if therapeutic response inadequate, but weigh against fetal risks.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
JAVADIN (hydroxychloroquine sulfate) requires baseline and periodic ophthalmologic exams due to risk of irreversible retinal toxicity, especially after cumulative dose >200g or use >5 years. Caution in patients with G6PD deficiency, psoriasis, and porphyria. Avoid concurrent use with QT-prolonging agents. Monitor renal and hepatic function.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Take with food or milk to reduce gastrointestinal upset.,Report any vision changes immediately, such as blurred vision, reading difficulties, or light sensitivity.,Do not exceed prescribed dose; overdose can be fatal.,Avoid alcohol as it may increase liver toxicity risk.,Use sunscreen and protective clothing to reduce photosensitivity.,Inform all healthcare providers you are taking JAVADIN.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JAVADIN vs CLOFARABINE, answered by our medical review team.
JAVADIN is a Antineoplastic Agent that works by JAVADIN is a synthetic flavonoid derivative that acts as a potent inhibitor of viral RNA-dependent RNA polymerase (Rd Rp), thereby blocking viral replication. It also modulates the host immune response by upregulating interferon signaling and reducing pro-inflammatory cytokine production.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JAVADIN and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JAVADIN is: 400 mg orally once daily. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JAVADIN and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JAVADIN is classified as Category C. FDA Pregnancy Category C. First trimester: potential for neural tube defects and cardiac malformations based on animal studies; limited human data. Second and third trimesters: ris. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.